Mayo Clinic

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Myosin Therapeutics is a privately-held biopharmaceutical company dedicated to developing innovative medications for central nervous system (CNS) disorders and other significant unmet medical needs. The company focuses on creating novel drugs that target cellular motor proteins, which are essential molecular machines that convert energy into mechanical work within cells. This unique approach enables the potential treatment of various disease states, including cancer. By harnessing the capabilities of these motor proteins, Myosin Therapeutics aims to advance therapeutic options and improve patient outcomes in challenging medical areas.

Delfina is a company that specializes in developing a personalized prenatal care system aimed at ensuring the safety of mothers and infants during pregnancy. By leveraging data and machine learning, Delfina's platform creates individualized pregnancy care plans that assess patient risk through various metrics. This approach not only enhances interventional workflows but also improves provider efficiency, facilitating early intervention in prenatal care. Delfina's commitment to data-driven insights is paving the way for clinical innovation, ultimately striving to deliver equitable and cost-effective healthcare solutions for expectant families.

Scaled Insights Inc. is a Toronto-based company that develops behavioral artificial intelligence software designed to enhance communication between clinicians and patients. By analyzing speech and complex human behavior data, the software enables healthcare professionals to understand patients' personalities and deliver personalized coaching aimed at promoting healthier behaviors. Scaled Insights' solutions extend beyond healthcare; they also cater to the fintech, insurtech, and human resources sectors, facilitating tasks such as handling insurance claims, matching financial advisors with clients, and identifying top performers. Founded in 2015, the company emphasizes data-driven decision-making to improve patient outcomes and operational efficiency while reducing costs. Additionally, Scaled Insights operates an office in Leeds, United Kingdom.

Jupiter Bioventures is a venture builder firm dedicated to supporting early-stage therapeutic projects. The company aims to de-risk these initiatives by carefully evaluating opportunities against specific investment criteria. By providing small amounts of seed capital, Jupiter Bioventures enables founders to cultivate their projects and advance their development. Through its focused approach, the firm plays a crucial role in fostering innovation in the therapeutic sector.

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

Clarapath, Inc. is a medical robotics company that specializes in automating laboratory processes for digital pathology applications. Founded in 2011 and headquartered in New York, the company has developed Section Star, an automated device that streamlines microtomy through a tape transfer method. Clarapath provides a range of services, including routine histology, pathology consultation, whole slide imaging, quantitative image analysis, and long-term data management. Its anatomic pathology laboratory caters to both human and animal digital pathology needs, serving academic researchers and clinical laboratories. The company aims to enhance the quality and efficiency of lab medicine while reducing costs and labor-related delays. By integrating its technologies, Clarapath facilitates real-time access to tissue samples, thereby standardizing and simplifying the histology process and improving safety and throughput in laboratory settings.

Endogenex is a medical technology company founded in 2017 that focuses on developing an innovative endoscopic procedure to assist patients with type 2 diabetes in managing their blood glucose levels. The company has created a unique therapy that employs pulsed electric fields to promote the regeneration of the duodenal mucosa, which contributes to enhanced glycemic control. By providing this novel treatment option, Endogenex aims to improve the quality of life for individuals living with type 2 diabetes.

JOGO Health is a virtual care company that specializes in digital therapeutics aimed at treating pain, neuromuscular conditions, and pelvic floor disorders. The company utilizes a combination of an AI-driven mobile app and wearable wireless sensors to deliver clinically proven interventions. These technologies offer treatment protocols and interactive games designed to enhance muscle relaxation, movement coordination, and neuromuscular reeducation. By leveraging the brain's neuroplasticity, JOGO Health enables healthcare providers to improve patient adherence to rehabilitation, ultimately leading to better health outcomes for individuals suffering from conditions such as stroke, chronic pain, and pelvic health issues.

AccuLine is a digital healthcare company focused on preventing heart attacks by offering innovative solutions for early detection of coronary artery disease (CAD). The company is developing CORA, a non-invasive examination technology that provides a smart, accurate, and user-friendly alternative to traditional stress tests. By streamlining the detection process, CORA enables healthcare providers to identify CAD more swiftly and cost-effectively, ultimately aiming to save millions of lives worldwide through timely intervention.

Qlaris Bio, Inc. is a clinical-stage biotechnology company based in Wellesley, Massachusetts, focused on developing innovative therapies for serious ophthalmic diseases. Founded in 2017, the company is working on QLS-101, a therapy aimed at reducing intraocular pressure, a critical factor in conditions such as glaucoma. Qlaris Bio explores novel mechanisms to address episcleral venous pressure, which significantly contributes to intraocular pressure, thereby aiming to mitigate the risk of blindness associated with both Primary Open Angle Glaucoma and Normal Tension Glaucoma. The company also targets high unmet medical needs in pediatric rare diseases related to intraocular pressure disturbances, where effective treatment options are currently limited.

PinkDx is a biotechnology company specializing in women's health. It develops molecular tests to improve diagnostic outcomes for women with vague gynecological cancer symptoms, offering alternatives to invasive procedures. This enables more comfortable and efficient resolution of health concerns, providing timely and positive impacts on patients' lives.

Collaborative Robotics is a team of innovators and builders redefining the future of human-robot interaction. A future in which robots are trustworthy extensions of the environment. They operate, adapt, and react in response.

UpDoc is a technology-enabled services firm that offers the world's first unique conversational AI platform for autonomous prescription management.

vMocion, LLC is a Scottsdale, Arizona-based company that specializes in developing innovative technology for virtual reality (VR) and augmented reality (AR) applications. The company's core offering is the 3v™ Platform, which utilizes galvanic vestibular stimulation (GVS) to create a realistic sensation of three-dimensional movement in digital environments. This technology converts 2D and 3D media into synchronized three-dimensional movement data, enhancing user experience in various media and entertainment applications. vMocion holds an exclusive global license for Mayo Clinic's GVS patents and algorithms, allowing it to integrate this technology with devices such as head-mounted displays, smartphones, and televisions. Founded in 2015, vMocion aims to mitigate virtual reality sickness and improve immersion for users, positioning itself as a key player in the evolving landscape of immersive media experiences.

Abridge Inc. is a healthcare technology company founded in September 1999, focused on enhancing communication in medical settings through innovative tools. The company utilizes generative AI to automate the transcription and summarization of patient-clinician conversations, converting these interactions into structured clinical notes in real-time. This platform integrates seamlessly with Electronic Health Record (EHR) systems, significantly reducing the need for manual note-taking. By generating clear and understandable summaries, Abridge improves patient comprehension of medical discussions and ensures that relevant documentation is accurately recorded in patient files. Additionally, the company emphasizes data security and patient privacy, adhering to healthcare regulations while providing a customizable interface that caters to individual patient needs.

Nucleus RadioPharma is a company focused on enhancing access to innovative radiopharmaceuticals for cancer patients. It is dedicated to developing technologies that modernize the clinical development, manufacturing, and supply chain processes associated with these therapies. By specializing in novel treatments and technologies, Nucleus RadioPharma aims to improve the diagnosis and treatment of various cancers, ensuring that healthcare professionals can effectively utilize these advanced medical solutions.

InfoBionic, Inc., founded in 2011 and based in Lowell, Massachusetts, specializes in remote patient monitoring and cardiac diagnostic services through its cloud-based platform, MoMe™. The MoMe System is designed to enhance the detection of cardiac arrhythmias, allowing healthcare providers to access vital patient data anytime and anywhere. By replicating in-hospital telemetry data, the platform streams continuous electrocardiogram, respiration, and motion data to the cloud for real-time analysis. This innovation aims to improve clinical efficiency and patient care, enabling physicians to monitor and treat cardiac complications effectively.

AccuLine is a digital healthcare company focused on preventing heart attacks by offering innovative solutions for early detection of coronary artery disease (CAD). The company is developing CORA, a non-invasive examination technology that provides a smart, accurate, and user-friendly alternative to traditional stress tests. By streamlining the detection process, CORA enables healthcare providers to identify CAD more swiftly and cost-effectively, ultimately aiming to save millions of lives worldwide through timely intervention.

The Contract Network is a developer of a digital collaborative platform designed to enhance the efficiency of clinical trial agreements. The platform focuses on accelerating contract negotiations and simplifying compliance processes, facilitating multi-party transactions. By providing a neutral environment for all parties involved, it enables businesses to negotiate agreements more effectively while promoting transparency and positive outcomes. This approach empowers advisors and streamlines the management of contract compliance, ultimately improving the overall efficiency of clinical trial collaborations.

Collaborative Robotics is a team of innovators and builders redefining the future of human-robot interaction. A future in which robots are trustworthy extensions of the environment. They operate, adapt, and react in response.

Basys.ai is a company that specializes in automating prior authorization and utilization management for health plans and payers through an AI-driven platform. Its proprietary technology employs machine learning to digitize and encode payer policies, significantly reducing the time needed for implementation by up to nine months. The platform aims to enhance communication between patients and healthcare providers, streamline administrative processes, and improve patient outcomes. By focusing on a data-centric approach, Basys.ai helps organizations optimize care delivery while minimizing costs associated with administrative tasks and medical procedures.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

AccurKardia is a diagnostics software company specializing in ECG-led technology aimed at enhancing patient outcomes and saving lives worldwide. The company's flagship product, AccurECG™, is a cloud-based, FDA-cleared software that enables fully automated, near real-time interpretation of ECG data. AccurKardia has developed additional solutions, including AK+ Guard™, an AI-driven tool for early detection of hyperkalemia using Lead I ECG data, which has received FDA Breakthrough Device Designation. The company also created the AK-AVS™ model for aortic stenosis detection, which similarly attained Breakthrough Device Designation. AccurKardia's innovative platform combines proprietary artificial intelligence with traditional techniques to deliver clinical-grade ECG analytics, assisting cardiac monitoring companies in analyzing ECGs from various devices. The company has participated in notable accelerator programs, including the 2024 Cohort of MedTech Innovator and the American Heart Association’s Heart and Brain Health Accelerator track, further establishing its commitment to advancing cardiovascular health technology.

Medivis is a developer of advanced medical imaging technology that utilizes augmented reality and artificial intelligence to enhance surgical operations. The company's innovative platform enables physicians to overlay holographic images directly onto patients during procedures, facilitating precise decision-making in the operating room. By integrating these technologies, Medivis aims to improve surgical outcomes and streamline the workflow for healthcare professionals, ultimately advancing the field of surgical navigation.

MediView, LLC is a medical device company based in Cleveland, Ohio, established in 2017. The company specializes in developing an augmented reality surgical navigation system designed to enhance the surgical process for healthcare providers. Its primary product, MediView, utilizes extended reality technology to offer real-time, fused-holographic visualization, which aids in the ablation and biopsy of cancerous tumors. This innovative approach allows surgeons to navigate procedures with greater accuracy and efficacy compared to conventional two-dimensional displays. Additionally, MediView's technology supports remote collaboration and telehealth, providing healthcare professionals with valuable insights and the ability to examine patients more effectively using three-dimensional holograms.

Lucem Health is a company focused on developing a remote diagnostics platform that integrates remote patient telemetry and biosensing devices with artificial intelligence algorithms. The platform is designed to enhance data ingestion, orchestration, and connectivity, which allows clinicians to deliver more effective continuous care. It supports the development and deployment of clinical AI models that facilitate point-of-care solutions, enabling healthcare providers to gain valuable insights directly from clinical data. By streamlining the execution of AI models and integrating these insights into clinical workflows, Lucem Health empowers both clinicians and consumers to improve health management and enhance overall well-being.

Mediwhale is a health diagnostics company that focuses on leveraging artificial intelligence to enhance the prevention of cardiovascular and kidney diseases. It operates a unique AI screening platform that assesses metabolic risks and diagnoses eye diseases through non-invasive retinal scans. The platform comprises several components, including RetiCVD for cardiovascular disease risk assessment, which utilizes coronary artery calcium scores to predict risks based on established guidelines. RetiCKD offers a chronic kidney disease risk assessment with improved predictive capabilities compared to traditional methods. Additionally, RetiEYE identifies common age-related eye diseases like diabetic retinopathy and glaucoma at their referable stages. Mediwhale's retinal-based systemic biomarkers have been clinically validated and are recognized in the medical community, supported by publications in reputable journals. Through its innovative approach, Mediwhale aims to establish a sustainable healthcare model that emphasizes early detection and intervention.

Cadence Neuroscience, Inc. is an early-stage company focused on developing innovative medical device therapies for epilepsy, central pain, and other neurological disorders. Founded in 2017 and based in Redmond, Washington, the company is leveraging core technology developed at the Mayo Clinic, which is currently under clinical evaluation. Cadence's implantable devices are designed to detect specific brain signals and deliver tailored electrical stimulation to modify neural circuit activity. This approach aims to enhance seizure control and improve treatment methods, offering medical practitioners a customizable solution for managing neurological conditions.

Healium is a mental fitness tool that offers a drugless approach to managing anxiety, sleep, addiction, and burnout. The company utilizes patented technology that connects to biometric data from consumer wearables, such as smartwatches and EEG headbands, allowing users to monitor their brainwaves and heart rate. This information is used to create a reactive, immersive media experience that adapts to the user's bio-data. Healium's unique platform has been validated by eight peer-reviewed studies, demonstrating its effectiveness in reducing anxiety and improving mood within minutes. By leveraging existing sensors and devices, Healium provides a controlled virtual and augmented reality environment for users seeking to enhance their mental well-being.

R-Zero is a company specializing in smart building technology and biosafety solutions aimed at enhancing indoor environments. It offers a suite of products designed to improve workforce productivity and optimize real estate utilization while promoting health and safety. R-Zero's portfolio includes advanced indoor air quality and comfort monitoring systems, high-efficiency HVAC filtration, occupancy-based building controls, and space utilization sensors. Additionally, the company provides mobile UV-C units that effectively disinfect large spaces, aiding in the reduction of infectious disease transmission. With a focus on operational efficiency, R-Zero's connected platform delivers real-time insights that empower building owners and operators to adapt their properties for future demands while ensuring a safe and productive environment for tenants.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

Nucleus RadioPharma is a company focused on enhancing access to innovative radiopharmaceuticals for cancer patients. It is dedicated to developing technologies that modernize the clinical development, manufacturing, and supply chain processes associated with these therapies. By specializing in novel treatments and technologies, Nucleus RadioPharma aims to improve the diagnosis and treatment of various cancers, ensuring that healthcare professionals can effectively utilize these advanced medical solutions.

Genomadix is a company that specializes in developing molecular testing technologies aimed at addressing infectious diseases, precision medicine, and water safety. It has created a diagnostic platform that incorporates a portable molecular analyzer utilizing polymerase chain reaction (PCR) technology. This innovative approach allows for quick and accurate test results to be generated outside of traditional healthcare settings. By facilitating rapid diagnostics, Genomadix enables healthcare professionals and patients to make informed, real-time healthcare decisions, thereby improving the overall quality of care and response to various health challenges.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Diagnostic Robotics Ltd is an Israeli company, founded in 2017 and headquartered in Tel Aviv, that specializes in developing artificial intelligence solutions for the healthcare sector. The company offers a signal-agnostic AI system designed to assist healthcare insurers, providers, and patients by creating predictive analytics models. These models aim to address significant clinical and financial challenges faced by the healthcare industry, ultimately optimizing clinical program performance and improving return on investment. By enabling healthcare systems to deliver more effective care at reduced costs, Diagnostic Robotics facilitates informed decision-making and proactive interventions in patient care.

Midday is an app that leverages AI, sensor technology, and digital therapeutics to support women on their menopause journey using personalized insights that illuminate what is happening physically and emotionally during menopause, providing the right intervention at the right time to manage menopause symptoms and promote healthy aging.

Ordr, Inc. is a cybersecurity company that specializes in securing Internet of Things (IoT) devices. Founded in 2015 and based in Santa Clara, California, Ordr offers a platform that utilizes machine learning and deep packet inspection to identify and monitor every connected device within an enterprise. The company's Systems Control Engine, a software-as-a-service solution, autonomously classifies devices, regulates network traffic, and enforces access policies to enhance security. Ordr serves various industries, including healthcare, manufacturing, retail, public venues, and logistics, providing real-time asset inventory and addressing risks and compliance needs. Organizations around the world rely on Ordr's technology to safeguard their networks and streamline IT operations.

Olive Diagnostics has developed an innovative passive urine analysis sensor that can be mounted on any toilet, enabling continuous health monitoring through urinalysis. This sensor utilizes a combination of spectroscopy and artificial intelligence to analyze the urine stream and provide real-time health alerts to users. By uploading data to a cloud-based platform, Olive Diagnostics facilitates ongoing biomarker tracking for various health indicators such as hydration, alcohol levels, pregnancy, and ovulation. This technology not only empowers individuals to gain insights into their health and body functions but also offers pharmaceutical and clinical research organizations a reliable method to monitor drug compliance and usage. By making urine lab services accessible at home, Olive Diagnostics aims to enhance disease detection and chronic disease management, particularly benefiting users in nonindustrial nations.

Karkinos Healthcare is a technology-driven platform that focuses on oncology, aiming to provide accessible cancer care and early diagnosis of common cancers. The company develops comprehensive healthcare solutions that bring cancer services closer to patients, ensuring that access and affordability do not hinder individuals from receiving necessary care. By emphasizing early detection and diagnosis, Karkinos Healthcare strives to improve patient outcomes and make cancer care more inclusive for everyone.

Vyriad, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies through the use of engineered viruses. These therapies, which include oncolytic immunovirotherapy products derived from oncolytic vesicular stomatitis virus and oncolytic measles virus platforms, are designed to selectively target and destroy cancer cells while sparing normal tissues. Vyriad's innovative approach aims to not only treat cancer but also to stimulate immune responses that can prevent recurrence. Additionally, the company is engaged in creating diagnostic and theranostic tests to accurately predict patient responses to its immunovirotherapy treatments. Vyriad's foundational research is supported by collaboration with prominent institutions such as the Mayo Clinic and the University of Miami. Established in 2012, Vyriad is headquartered in Rochester, Minnesota.

Theator Inc. is a surgical intelligence platform based in San Mateo, California, focused on enhancing surgeon performance through the use of artificial intelligence and computer vision. Founded in 2018, the company offers a personalized video platform called Minutes, which analyzes and houses video data from surgical procedures. This platform includes content management software and a visual operative report featuring analytics, allowing surgeons to review past surgeries for educational purposes. By extracting and annotating critical moments from real-world procedures, Theator enables surgeons to gain valuable insights into their performances and those of their peers, thereby promoting continuous improvement and expertise within the operating room. Theator collaborates with innovative surgeons and hospitals to foster a more transparent surgical environment.

Collider activates, connects, and empowers early-stage entrepreneurs in Rochester, Minnesota.

Medically Home Group, Inc. is a Boston-based company that specializes in delivering virtual hospital services, enabling patients to receive medical care in the comfort of their homes. Founded in 2016, the company offers a comprehensive program that addresses various medical conditions, including heart failure, pneumonia, chronic obstructive pulmonary disease (COPD), and urinary tract infections, among others. By utilizing a technology-enabled platform, Medically Home connects patients with caregivers and facilitates monitoring and communication for individuals with high-acuity illnesses. This approach allows patients and their families to access centralized, on-demand acute medical care management, effectively shifting the focus of healthcare from traditional hospital settings to home-based care.

The Patient Company, LLC, founded in 2019 by Andrew Heuerman, specializes in the development and production of SimPull, an automated lateral patient transfer device. With locations in Grand Rapids, Michigan, and Scottsdale, Arizona, the company aims to enhance patient care by providing a motorized mechanical lifting device that allows a single care team member to safely and respectfully transfer patients. SimPull is designed to protect clinicians from injuries, reduce the average time required for transfers, and eliminate waste generated by disposable components of alternative products.

Tympany Medical focuses on advancing minimally invasive ear surgeries through innovative technology. The company has developed a specialized ear surgery device that provides a sterile endoscopic solution for complex procedures in otolaryngology. This device addresses key challenges related to the usability and flexibility of traditional endoscopes, allowing surgeons to benefit from enhanced visualization while preserving their two-handed operating techniques. By reducing the necessity for mastoidectomies, Tympany Medical aims to improve surgical outcomes and streamline the process of ear surgeries, ultimately enhancing patient care in the field of ENT.

SimBioSys is focused on advancing cancer care through its innovative Computational Microscope, which combines cutting-edge simulation techniques with extensive experimental datasets. This technology allows researchers to examine the cancer microenvironment, gaining insights into tumor behavior, cell phenotypes, and interactions with surrounding tissues. By transforming comprehensive diagnostic datasets into personalized virtual tumors, SimBioSys enhances decision-making for healthcare providers and improves patient experiences in cancer treatment. Ultimately, the platform aims to facilitate a deeper understanding of cancer dynamics, enabling more effective and tailored therapeutic approaches.

TripleBlind, Inc. is a Kansas City-based company incorporated in 2019 that provides an online platform enabling organizations to collaborate while safeguarding sensitive data and algorithms. The company specializes in privacy-enhancing computation, offering a software-only solution delivered through a simple API. TripleBlind focuses on sectors such as healthcare and financial services, utilizing innovations like federated learning and multi-party computation to enhance the scalability and efficiency of privacy-preserving technology. Its platform allows institutions to share and monetize regulated data without compromising privacy, ensuring compliance with regulations like HIPAA and GDPR. By facilitating collaboration around sensitive data without decryption, TripleBlind enables clients to generate new revenue, derive deeper insights, and improve modeling and analysis. The company is supported by notable investors including Accenture, General Catalyst, and The Mayo Clinic, and it integrates seamlessly with major cloud platforms.

Laplace Interventional is a medical device company focused on developing transcatheter tricuspid valve technology aimed at treating tricuspid regurgitation. The company's innovative prosthetic valve is delivered through a minimally invasive procedure, eliminating the need for open-heart surgery. This approach not only enhances patients' life expectancy but also significantly improves their quality of life by reducing the risk of future complications. Through its advancements in cardiac care, Laplace Interventional is dedicated to providing effective solutions for patients worldwide.

JOGO Health is a virtual care company that specializes in digital therapeutics aimed at treating pain, neuromuscular conditions, and pelvic floor disorders. The company utilizes a combination of an AI-driven mobile app and wearable wireless sensors to deliver clinically proven interventions. These technologies offer treatment protocols and interactive games designed to enhance muscle relaxation, movement coordination, and neuromuscular reeducation. By leveraging the brain's neuroplasticity, JOGO Health enables healthcare providers to improve patient adherence to rehabilitation, ultimately leading to better health outcomes for individuals suffering from conditions such as stroke, chronic pain, and pelvic health issues.

R-Zero is a company specializing in smart building technology and biosafety solutions aimed at enhancing indoor environments. It offers a suite of products designed to improve workforce productivity and optimize real estate utilization while promoting health and safety. R-Zero's portfolio includes advanced indoor air quality and comfort monitoring systems, high-efficiency HVAC filtration, occupancy-based building controls, and space utilization sensors. Additionally, the company provides mobile UV-C units that effectively disinfect large spaces, aiding in the reduction of infectious disease transmission. With a focus on operational efficiency, R-Zero's connected platform delivers real-time insights that empower building owners and operators to adapt their properties for future demands while ensuring a safe and productive environment for tenants.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

Medically Home Group, Inc. is a Boston-based company that specializes in delivering virtual hospital services, enabling patients to receive medical care in the comfort of their homes. Founded in 2016, the company offers a comprehensive program that addresses various medical conditions, including heart failure, pneumonia, chronic obstructive pulmonary disease (COPD), and urinary tract infections, among others. By utilizing a technology-enabled platform, Medically Home connects patients with caregivers and facilitates monitoring and communication for individuals with high-acuity illnesses. This approach allows patients and their families to access centralized, on-demand acute medical care management, effectively shifting the focus of healthcare from traditional hospital settings to home-based care.

Adaptive Phage Therapeutics, Inc. specializes in developing therapeutic solutions to combat the increasing threat of multi-drug resistant (MDR) bacteria. Founded in 2016 and based in Gaithersburg, Maryland, the company utilizes a unique resource known as PhageBank, which is an extensive and dynamic collection of bacteriophages—viruses that specifically target and attack harmful bacteria. Through a rapid system that matches these phages to individual patient bacterial infections, Adaptive Phage Therapeutics aims to enhance treatment options for patients suffering from MDR infections. Their innovative approach enables medical researchers to create tailored therapies that effectively detect and eliminate resistant bacterial strains.

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Glooko is a company that develops a remote patient-monitoring platform specifically designed for individuals with diabetes. This platform integrates with various diabetes devices, fitness wearables, and activity trackers to capture and sync health data. It provides comprehensive reports and analytics aimed at promoting behavior change and improving health outcomes. By enhancing communication between patients and healthcare providers, Glooko facilitates better management of diabetes and supports remote monitoring efforts. The platform is accessible on both Android and iOS devices, allowing users to conveniently track their diabetes-related information on their smartphones.

Nuvolo Technologies Corporation offers a cloud-based enterprise asset management platform designed to support the lifecycle management of assets in various sectors, including healthcare, manufacturing, and facilities management. Founded in 2013 and headquartered in Paramus, New Jersey, Nuvolo innovates on the ServiceNow platform to provide a user-friendly experience for mobile and online users. The company’s solutions encompass implementation, support, tracking, reporting, and analytics, aimed at optimizing operational efficiency and improving asset management. Nuvolo also emphasizes security, workflow automation, and accurate inventory data, making it a comprehensive choice for businesses looking to enhance their asset management capabilities. With additional offices in London, Sofia, and Pune, Nuvolo maintains a global presence through strategic partnerships with firms such as KPMG and Unisys.

TripleBlind, Inc. is a Kansas City-based company incorporated in 2019 that provides an online platform enabling organizations to collaborate while safeguarding sensitive data and algorithms. The company specializes in privacy-enhancing computation, offering a software-only solution delivered through a simple API. TripleBlind focuses on sectors such as healthcare and financial services, utilizing innovations like federated learning and multi-party computation to enhance the scalability and efficiency of privacy-preserving technology. Its platform allows institutions to share and monetize regulated data without compromising privacy, ensuring compliance with regulations like HIPAA and GDPR. By facilitating collaboration around sensitive data without decryption, TripleBlind enables clients to generate new revenue, derive deeper insights, and improve modeling and analysis. The company is supported by notable investors including Accenture, General Catalyst, and The Mayo Clinic, and it integrates seamlessly with major cloud platforms.

Diagnostic Robotics Ltd is an Israeli company, founded in 2017 and headquartered in Tel Aviv, that specializes in developing artificial intelligence solutions for the healthcare sector. The company offers a signal-agnostic AI system designed to assist healthcare insurers, providers, and patients by creating predictive analytics models. These models aim to address significant clinical and financial challenges faced by the healthcare industry, ultimately optimizing clinical program performance and improving return on investment. By enabling healthcare systems to deliver more effective care at reduced costs, Diagnostic Robotics facilitates informed decision-making and proactive interventions in patient care.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Adaptive Phage Therapeutics, Inc. specializes in developing therapeutic solutions to combat the increasing threat of multi-drug resistant (MDR) bacteria. Founded in 2016 and based in Gaithersburg, Maryland, the company utilizes a unique resource known as PhageBank, which is an extensive and dynamic collection of bacteriophages—viruses that specifically target and attack harmful bacteria. Through a rapid system that matches these phages to individual patient bacterial infections, Adaptive Phage Therapeutics aims to enhance treatment options for patients suffering from MDR infections. Their innovative approach enables medical researchers to create tailored therapies that effectively detect and eliminate resistant bacterial strains.

Ordr, Inc. is a cybersecurity company that specializes in securing Internet of Things (IoT) devices. Founded in 2015 and based in Santa Clara, California, Ordr offers a platform that utilizes machine learning and deep packet inspection to identify and monitor every connected device within an enterprise. The company's Systems Control Engine, a software-as-a-service solution, autonomously classifies devices, regulates network traffic, and enforces access policies to enhance security. Ordr serves various industries, including healthcare, manufacturing, retail, public venues, and logistics, providing real-time asset inventory and addressing risks and compliance needs. Organizations around the world rely on Ordr's technology to safeguard their networks and streamline IT operations.

Securisyn Medical, LLC is a medical technology company based in Highlands Ranch, Colorado, that specializes in the manufacture and supply of oxygen delivery systems for mechanically ventilated patients. Founded in 2011, the company focuses on enhancing patient safety and preventing unplanned extubation, which can lead to serious complications. Its innovative airway stabilization system features a ribbed endotracheal tube and an interlocking stabilizer, providing additional security for the airway and protecting critical components. Securisyn Medical serves healthcare providers and medical facilities across the United States, striving to reduce preventable deaths related to airway management while also decreasing overall healthcare costs. The company's commitment to ethical and sustainable practices underpins its mission to improve outcomes for patients, their families, and practitioners.

Progentec Diagnostics, Inc. is a company focused on developing innovative diagnostic tests for managing systemic lupus erythematosus (SLE). Established in 2015 and headquartered in Oklahoma City, Oklahoma, the company has created the aiSLE DX platform, which offers tools like a flare prediction score to measure disease activity in SLE patients and an early diagnostic test for lupus. Progentec integrates advanced technology and collaborates with research institutions globally, aiming to address significant unmet needs in diagnostic interventions. The company's mission centers on improving disease management and reducing disease incidence through enhanced screening and early detection.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Novome Biotechnologies, Inc. is a biotechnology company that focuses on engineering bacteria from the human gut to develop innovative treatments for chronic diseases. Its proprietary platform, which allows for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs), is designed to provide sustained therapeutic effects. Novome's lead preclinical program targets hyperoxaluria by developing a therapeutic strain of bacteria that degrades oxalate, thereby preventing kidney stone formation. The company aims to leverage its synthetic biology tools to expand its applications into additional health conditions, enhancing its ability to deliver precise therapeutic activities through engineered gut microbiota. Founded in 2015, Novome is headquartered in South San Francisco, California.

Elysium Health, Inc. develops and produces health supplements focused on cellular health, long-term brain health, and biological age testing. Founded in 2014 and based in New York, the company sells its products online, aiming to enhance health and longevity through scientifically backed solutions. Elysium collaborates with scientists, clinicians, and health professionals globally to identify and formulate natural compounds. Its flagship product features a proprietary combination of ingredients designed to support overall well-being at the cellular level, addressing contemporary health challenges with a foundation in scientific research.

HuidaGene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of gene therapies for single-gene disorders and is expanding its focus to neurodegenerative diseases and vision disorders. HuidaGene employs its proprietary CRISPR-based and AI-driven HG-PRECISE platform to create potentially curative therapies. Among its clinical programs, HuidaGene is advancing HG004 for RPE65-associated retinal disease, HG202 for neovascular age-related macular degeneration, HG204 for MECP2 duplication syndrome, and HG302 for Duchenne muscular dystrophy. Several of these therapies have received orphan drug designations and rare pediatric disease designations from regulatory authorities. In addition to its clinical initiatives, the company is exploring preclinical programs, including HG303 for amyotrophic lateral sclerosis and a CRISPR RNA-editing therapy for Alzheimer’s disease.

NewCompliance is a healthcare technology company focused on enhancing the quality and safety of patient care through its innovative platform. The company collaborates with industry partners such as Stryker, Medtronic, Skytron, and Philips to deliver interoperable IT solutions. Its flagship product, the ACTIQ platform, offers predictive dashboarding and analytics, allowing medical personnel to access real-time feedback and management information. This technology is designed to support caregivers in departments such as surgery, emergency care, and intensive care, ultimately aiming to reduce costs, improve hospital safety, and enhance patient satisfaction throughout the surgical patient journey. By prioritizing efficiency and effectiveness, NewCompliance positions itself as a leader in the healthcare technology sector.

FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals. The company works at the nexus of haptics, machine learning, and immersive technologies (XR). FundamentalVR was established in 2012 by Chris Scattergood in London, England.

AtriAN Medical is an Irish medical device company based in Galway, specializing in innovative treatments for atrial fibrillation. The company has commercialized technology developed at the Mayo Clinic, focusing on a unique approach that utilizes micro Pulsed Electric Fields (mPEF) to selectively ablate hyperactive tissues while preserving surrounding myocardial tissue. AtriAN's device employs a catheter to deliver short pulses of electrical energy to the clusters of neuronal cells responsible for the condition. This method allows for effective treatment without causing damage to the heart muscle, offering physicians a new option in managing atrial fibrillation and improving patient outcomes.

Cadence Neuroscience, Inc. is an early-stage company focused on developing innovative medical device therapies for epilepsy, central pain, and other neurological disorders. Founded in 2017 and based in Redmond, Washington, the company is leveraging core technology developed at the Mayo Clinic, which is currently under clinical evaluation. Cadence's implantable devices are designed to detect specific brain signals and deliver tailored electrical stimulation to modify neural circuit activity. This approach aims to enhance seizure control and improve treatment methods, offering medical practitioners a customizable solution for managing neurological conditions.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Qlaris Bio, Inc. is a clinical-stage biotechnology company based in Wellesley, Massachusetts, focused on developing innovative therapies for serious ophthalmic diseases. Founded in 2017, the company is working on QLS-101, a therapy aimed at reducing intraocular pressure, a critical factor in conditions such as glaucoma. Qlaris Bio explores novel mechanisms to address episcleral venous pressure, which significantly contributes to intraocular pressure, thereby aiming to mitigate the risk of blindness associated with both Primary Open Angle Glaucoma and Normal Tension Glaucoma. The company also targets high unmet medical needs in pediatric rare diseases related to intraocular pressure disturbances, where effective treatment options are currently limited.

Safely Health operates an online platform designed to promote safe sexual practices by enabling users to import their test results and verify their STD and COVID-19 status. Founded in 2015 and based in Los Angeles, the company aims to create a trusted, private, and secure environment for individuals seeking to share their health information with potential partners. Safely Health is not just an app but a comprehensive healthcare initiative that collaborates with leading healthcare organizations, including Quest and Labcorp, as well as public health entities like the CDC. By partnering with nonprofit organizations, influencers, and social media platforms, Safely Health seeks to empower users to take control of their sexual health and reduce the spread of STDs, ultimately fostering a safer and more enjoyable dating experience.

GYANT is a digital front door solution for health systems that utilizes artificial intelligence to enhance patient navigation to appropriate care settings and in-network resources. By implementing digital patient journeys, GYANT enables health systems to effectively capture new patients and efficiently serve existing ones. The platform employs natural language processing to understand patients' needs, guiding them through their healthcare encounters. This not only improves patient engagement but also enhances care utilization, leading to better access to healthcare services. Additionally, GYANT contributes to process automation within health systems, ultimately resulting in lower costs and time savings for healthcare providers.

Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.

Giblib is a California-based company founded in 2015, headquartered in Los Angeles. It operates an online video community platform that serves as a resource for medical education, specifically targeting surgical procedures across various specialties. The platform allows surgeons to share curated medical lectures and surgical videos, providing valuable insights into surgical techniques and practices. By indexing every surgical procedure, Giblib enables medical students and practitioners to access high-quality educational content from experienced professionals, enhancing their understanding of medicine and surgery.

StemoniX Inc. is a biotechnology company specializing in stem cell technologies to enhance drug discovery and personalized medicine. Founded in 2014 and headquartered in Minneapolis, Minnesota, with an additional office in La Jolla, California, StemoniX offers a platform that focuses on the 3-D printing of stem-cell derived human tissues. This innovative approach allows for the creation of custom drug discovery models and facilitates the development of living cells in larger formats, addressing various medical conditions such as heart disease, dementia, breast cancer, autism, and ALS. The company's platform also operationalizes human induced pluripotent stem cell (iPSC) disease models for high-throughput screening, improving the research process for neurotoxicity and other drug screening efforts.

Caraway Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases through the modulation of mitophagy and autophagy. By targeting genetically defined pathways, the company aims to create small molecules that restore cellular balance and address the underlying mechanisms of diseases such as Parkinson's disease and amyotrophic lateral sclerosis. Founded in 2018 and based in Cambridge, Massachusetts, Caraway Therapeutics seeks to improve the lives of patients affected by these debilitating conditions by leveraging its expertise in cellular degradation processes. The company was previously known as Rheostat Therapeutics, Inc. before rebranding in October 2019.

Marigold Health operates a social network community platform designed to provide text-based group therapies for individuals facing mental health and substance use challenges. The platform facilitates anonymous support groups, allowing patients to engage with one another and receive guidance from coaches who have personal recovery experiences. By leveraging AI-augmented chat support, Marigold Health enhances the capacity of care teams while ensuring that patients receive personalized, stigma-free assistance. The company collaborates directly with treatment providers and managed care organizations within the Medicaid market to improve access to on-demand group therapies and foster a supportive community for recovery.

Ambient Clinical Analytics, Inc. develops healthcare data assimilation and decision support tools aimed at enhancing patient care in intensive care units, operating rooms, and emergency departments. The company's flagship product, AWARE, integrates with various electronic health record systems and bedside monitors to deliver crucial patient information on a single-screen dashboard, facilitating real-time clinical decision-making. Additionally, Ambient offers the Mayo Clinic YES Board, which enhances patient flow by providing real-time situational awareness. The company also specializes in syndromic surveillance solutions, including Sepsis DART, which aids in the detection and confirmation of sepsis, and the Ventilator-Induced Lung Injury Sniffer, designed for ventilator monitoring. Furthermore, Ambient provides the Synthesis Platform, which serves as an integration tool for AWARE and the Mayo Clinic solutions. Founded in 2013 and headquartered in Rochester, Minnesota, Ambient Clinical Analytics focuses on reducing healthcare costs and improving patient outcomes through its innovative tools and technology.

Vineti, Inc. is a technology company that specializes in developing solutions for the therapeutic delivery of personalized medicine, particularly focusing on cell and gene therapies. Founded in 2016 and headquartered in San Francisco, California, with additional offices in Bethesda, Maryland, and Yerevan, Armenia, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform streamlines and automates patient-centric supply chains, facilitating the efficient management of operations, manufacturing, quality control, and regulatory compliance for advanced therapies, including CAR-T cell therapies for late-stage cancer. Vineti's solutions aim to enhance patient access to life-saving treatments while addressing the challenges faced by patients, healthcare providers, pharmaceutical companies, and regulators in the commercialization of personalized medicine. By providing tools for supply chain orchestration and maintaining an audit trail for the handling of cell products, Vineti positions itself as a critical player in the evolving landscape of personalized therapeutics.

Geneticure Inc. is a pharmacogenetic testing company based in Eden Prairie, Minnesota, founded in 2012. The company specializes in developing tests that enable personalized medicine, particularly for patients with hypertension. Geneticure has created a patented cheek-swab test that predicts individual responses to high blood pressure medications and therapies. The testing process involves DNA extraction and genotyping, and the results are directly provided to healthcare providers alongside a summary of the genetic findings and a decision tree for treatment optimization. These tools are designed to assist clinicians in determining the most effective treatment methods for managing high blood pressure, ultimately allowing patients to utilize painless and affordable at-home testing to reach their blood pressure goals. Geneticure is backed by the Mayo Clinic, emphasizing its commitment to clinical evidence and personalized patient care.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Progentec Diagnostics, Inc. is a company focused on developing innovative diagnostic tests for managing systemic lupus erythematosus (SLE). Established in 2015 and headquartered in Oklahoma City, Oklahoma, the company has created the aiSLE DX platform, which offers tools like a flare prediction score to measure disease activity in SLE patients and an early diagnostic test for lupus. Progentec integrates advanced technology and collaborates with research institutions globally, aiming to address significant unmet needs in diagnostic interventions. The company's mission centers on improving disease management and reducing disease incidence through enhanced screening and early detection.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

Qrativ, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in developing an AI-driven healthcare platform, known as Darwin.ai, which focuses on identifying new treatments for rare diseases with unmet medical needs. By leveraging machine learning and artificial intelligence, Qrativ's drug purposing platform facilitates the discovery and development of new uses for existing molecules, aiming to provide patients with access to treatments that are currently unavailable in the market. The company collaborates with biotechnology and pharmaceutical firms to enhance their research and development efforts in addressing these critical healthcare challenges.

Evelo Biosciences, Inc., established in 2015, is a biotechnology company based in Cambridge, Massachusetts. It specializes in the discovery and development of a novel class of medicines known as monoclonal microbials, which are orally delivered and designed to modulate systemic immunology and biology by interacting with human cells in the gut. Evelo's pipeline includes EDP1815, currently in a Phase 1b clinical trial for psoriasis and atopic dermatitis, and EDP1503, in a Phase 1/2 study for various cancer types, including colorectal, triple-negative breast, and melanoma. The company aims to apply this innovative approach across a broad range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory conditions, and cancer.

DayTwo Ltd. is a precision nutrition company headquartered in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome insights to improve health outcomes and prevent diseases such as diabetes, prediabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo employs microbiome sequencing to create personalized dietary recommendations, known as Food Prescriptions™, tailored to individual responses to food. This approach helps manage blood sugar levels, enhance energy, control hunger, and promote weight loss. DayTwo delivers its services through a digital platform and mobile application, enabling users to track their progress and communicate with certified diabetes care specialists and registered dietitians. By emphasizing personalized nutrition based on scientific research, DayTwo aims to empower patients to lead healthier lives through informed dietary choices.

Glooko is a company that develops a remote patient-monitoring platform specifically designed for individuals with diabetes. This platform integrates with various diabetes devices, fitness wearables, and activity trackers to capture and sync health data. It provides comprehensive reports and analytics aimed at promoting behavior change and improving health outcomes. By enhancing communication between patients and healthcare providers, Glooko facilitates better management of diabetes and supports remote monitoring efforts. The platform is accessible on both Android and iOS devices, allowing users to conveniently track their diabetes-related information on their smartphones.

Vineti, Inc. is a technology company that specializes in developing solutions for the therapeutic delivery of personalized medicine, particularly focusing on cell and gene therapies. Founded in 2016 and headquartered in San Francisco, California, with additional offices in Bethesda, Maryland, and Yerevan, Armenia, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform streamlines and automates patient-centric supply chains, facilitating the efficient management of operations, manufacturing, quality control, and regulatory compliance for advanced therapies, including CAR-T cell therapies for late-stage cancer. Vineti's solutions aim to enhance patient access to life-saving treatments while addressing the challenges faced by patients, healthcare providers, pharmaceutical companies, and regulators in the commercialization of personalized medicine. By providing tools for supply chain orchestration and maintaining an audit trail for the handling of cell products, Vineti positions itself as a critical player in the evolving landscape of personalized therapeutics.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Sensely is a company that develops a conversational platform aimed at enhancing the experience of insurance plan members and patients. By utilizing avatar and chatbot technology, Sensely's platform provides virtual assistant solutions for insurance companies, pharmaceutical clients, and hospital systems globally. This innovative approach allows enterprises to engage with their members in a more meaningful way, merging the empathy inherent in human conversation with the efficiency and scalability offered by technology. Through this platform, Sensely seeks to improve brand preference and influence user behavior, ultimately transforming the way healthcare organizations interact with their stakeholders.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.